Tumor-associated CD75s- and iso-CD75s-gangliosides are potential targets for adjuvant therapy in pancreatic cancer

Molecular Cancer Therapeutics

Volumn 7, Issue 8, 2008, Pages 2464-2475

  Distler, Ute ^a   Souady, Jamal ^a   Hülsewig, Marcel ^a   Drmić Hofman, Irena ^c   Haier, Jörg ^b   Denz, Axel ^d   Grützmann, Robert ^d   Pilarsky, Christian ^d   Senninger, Norbert ^b   Dreisewerd, Klaus ^a   Berkenkamp, Stefan ^e   Schmidt, M Alexander ^a   Peter Katalinić, Jasna ^a   Müthing, Johannes ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UNIVERSITY HOSPITAL SPLIT   (Croatia)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e Sequenom GmbH Hamburg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GANGLIOSIDE; UNCLASSIFIED DRUG; VISCUMIN;

ADJUVANT THERAPY; ARTICLE; CANCER THERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; MASS SPECTROMETRY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS; THIN LAYER CHROMATOGRAPHY;

ADENOCARCINOMA; ANTIBODIES, NEOPLASM; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CHROMATOGRAPHY, THIN LAYER; GANGLIOSIDES; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSCOPY, FLUORESCENCE; PANCREATIC NEOPLASMS; RECOMBINANT PROTEINS; RIBOSOME INACTIVATING PROTEINS, TYPE 2; SIALYLTRANSFERASES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TOXINS, BIOLOGICAL; TUMOR MARKERS, BIOLOGICAL;

EID: 53349160475     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0353     Document Type: Article

References (42)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
3. Pipas JM, Barth RJ, Zaki B, et al. Docetaxel/gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma. Ann Surg Oncol 2005;12:995-1004.
4. Ghaneh P, Costello E, Neoptolemos JP. Biology and management of pancreatic cancer. Gut 2007;56:1134-52.
5. Levery SB. Glycosphingolipid structural analysis and glycosphingolipidomics. Methods Enzymol 2005;405:300-69.
6. Feizi T. Carbohydrate-mediated recognition systems in innate immunity. Immunol Rev 2000;173:79-88.
7. Hakomori S. Cell adhesion/recognition and signal transduction through glycosphingolipid microdomain. Glycoconj J 2000;17:143-51.
8. Sonnino S, Prinetti A, Mauri L, Chigorno V, Tettamanti G. Dynamic and structural properties of sphingolipids as driving forces for the formation of membrane domains. Chem Rev 2006;106:2111-25.
9. Feizi T. Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are onco-developmental antigens. Nature 1985;314:53-7.
10. Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res 1996;56:5309-18.
11. Fredman P, Hedberg K, Brezicka T. Gangliosides as therapeutic targets for cancer. BioDrugs 2003;17:155-67.
12. Månsson JE, Fredman P, Nilsson O, Lindholm L, Holmgren J, Svennerholm L. Chemical structure of carcinoma ganglioside antigens defined by monoclonal antibody C-50 and some allied gangliosides of human pancreatic adenocarcinoma. Biochim Biophys Acta 1985;834:110-7.
13. Mason D, André P, Bensussan A, et al. CD antigens 2002. Blood 2002;99:3877-80.
14. Distler U, Hülsewig M, Souady J, et al. Matching IR-MALDI-o-TOF mass spectrometry with the TLC overlay binding assay and its clinical application for tracing tumor-associated glycosphingolipids in hepatocellular and pancreatic cancer. Anal Chem 2008;80:1835-46.
15. Müthing J, Meisen I, Kniep B, et al. Tumor-associated CD75s gangliosides and CD75s-bearing glycoproteins with Neu5Acα2-6Galβ1- 4GlcNAc-residues are receptors for the anticancer drug rViscumin. FASEB J 2005;19:103-5.
16. Müthing J, Burg M, Möckel B, et al. Preferential binding of the anticancer drug rViscumin (recombinant mistletoe lectin) to terminally α2-6-sialylated neolacto-series gangliosides. Glycobiology 2002;12:485-97.
17. Müthing J, Meisen I, Bulau P, et al. Mistletoe lectin I is a sialic acid-specific lectin with strict preference to gangliosides and glycoproteins with terminal Neu5Acα2-6Galβ1-4GlcNAc residues. Biochemistry 2004;43:2996-3007.
18. Schöffski P, Riggert S, Fumoleau P, et al. Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group. Ann Oncol 2004;15:1816-24.
19. Schöffski P, Breidenbach I, Krauter J, et al. Weekly 24 h infusion of aviscumine (rViscumin): a phase I study in patients with solid tumours. Eur J Cancer 2005;41:1431-8.
20. Grützmann R, Pilarsky C, Ammerpohl O, et al. Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. Neoplasia 2004;6:611-22.
21. Sobin LH, Wittekind C, editors. TNM classification of malignant tumours. 5th ed. New York: Wiley-Liss; 1997. pp. 123-30.
22. Müthing J, Unland F, Heitmann D, et al. Different binding capacities of influenza A and Sendai viruses to gangliosides from human granulocytes. Glycoconj J 1993;10:120-6.
23. Chester MA. IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN). Nomenclature of glycolipids. Recommendations 1997. Glycoconj J 1999;16:1-6.
24. Meisen I, Peter-Katalinić J, Müthing J. Discrimination of neolactoseries gangliosides with α2-3- and α2-6-linked N-acetylneuraminic acid by nanoelectrospray ionization low-energy collision-induced dissociation tandem quadrupole TOF MS. Anal Chem 2003;75:5719-25.
25. Müthing J, Spanbroek R, Peter-Katalinić J, et al. Isolation and structural characterization of fucosylated gangliosides with linear poly-N-acetyllactosaminyl chains from human granulocytes. Glycobiology 1996;6:147-56.
26. Schweppe CH, Bielaszewska M, Pohlentz G, et al. Glycosphingolipids in vascular endothelial cells: relationship of heterogeneity in Gb3Cer/CD77 receptor expression with differential Shiga toxin 1 cytotoxicity. Glycoconj J 2008;25:291-304.
27. Dreisewerd K, Múthing J, Rohlfing A, et al. Analysis of gangliosides directly from thin-layer chromatography plates by infrared matrix-assisted laser desorption/ionization orthogonal time-of-flight mass spectrometry with a glycerol matrix. Anal Chem 2005;77:4098-107.
28. Macher BA, Lee WM, Westrick MA. Glycosphingolipids of normal and leukemic human leukocytes. Mol Cell Biochem 1982;47:81-95.
29. Kannagi R, Yin J, Miyazaki K, Izawa M. Current relevance of incomplete synthesis and neo-synthesis for cancer-associated alteration of carbohydrate determinants - Hakomori's concepts revisited. Biochim Biophys Acta 2008;1780:525-31.
30. Chu KU, Ravindranath MH, Gonzales A, et al. Gangliosides as targets for immunotherapy for pancreatic adenocarcinoma. Cancer 2000;88:1828-36.
31. Lundquist JJ, Toone EJ. The cluster glycoside effect. Chem Rev 2002;102:555-78.
32. Durrant LG, Harding SJ, Green NH, Buckberry LD, Parsons T. A new anticancer glycolipid monoclonal antibody, SC104, which directly induces tumor cell apoptosis. Cancer Res 2006;66:5901-9.
33. Ecsedy JA, Yohe HC, Bergeron AJ, Seyfried TN. Tumor-infiltrating macrophages influence the glycosphingolipid composition of murine brain tumors. J Lipid Res 1998;39:2218-27.
34. Kiguchi K, Henning-Chubb CB, Huberman E. Glycosphingolipid patterns of peripheral blood lymphocytes, monocytes, and granulocytes are cell specific. J Biochem 1990;107:8-14.
35. Taki T, Yamamoto K, Takamatsu M, et al. Accumulation of gangliosides with N-acetylneuraminosyl(α2-6)lactosamine structure in primary human hepatoma. Cancer Res 1990;50:1284-90.
36. Dall'Olio F, Chiricolo M. Sialyltransferases in cancer. Glycoconj J 2001;18:841-50.
37. Hedlund M, Ng E, Varki A, Varki NM. α2-6-Linked sialic acids on N-glycans modulate carcinoma differentiation in vivo. Cancer Res 2008;68:388-94.
38. Valentiner U, Pfüller U, Baum C, Schumacher U. The cytotoxic effect of mistletoe lectins I, II and III on sensitive and multidrug resistant human colon cancer cell lines in vitro. Toxicology 2002;171:187-99.
39. Bantel H, Engels IH, Voelter W, Schulze-Osthoff K, Wesselborg S. Mistletoe lectin activates caspase-8/FLICE independently of death receptor signaling and enhances anticancer drug-induced apoptosis. Cancer Res 1999;59:2083-90.
40. Hostanska K, Vuong V, Rocha S, et al. Recombinant mistletoe lectin induces p53-independent apoptosis in tumour cells and cooperates with ionising radiation. Br J Cancer 2003;88:1785-92.
41. Schumacher U, Feldhaus S, Mengs U. Recombinant mistletoe lectin (rML) is successful in treating human ovarian cancer cells transplanted into severe combined immunodeficient (SCID) mice. Cancer Lett 2000;150:171-5.
42. Elsässer-Beile U, Ruhnau T, Freudenberg N, Wetterauer U, Mengs U. Antitumoral effect of recombinant mistletoe lectin on chemically induced urinary bladder carcinogenesis in a rat model. Cancer 2001;91:998-1004.